ArticleMolecular biology reports2026
Somatic mutation profiling by NGS-based liquid biopsy in advanced non-small cell lung cancer: frequency, clinical correlates, and prognostic significance.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Novel HomozygousLife (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiquid biopsy-based next-generation sequencing (NGS) of plasma cell-free DNA (cfDNA) - including its tumour-derived fraction known as circulating tumor DNA (ctDNA) - enables non-invasive, comprehensive mutational profiling in advanced non-small cell lung cancer (NSCLC). However, data on multi-gene plasma NGS panels in Turkish populations remain limited.
methodsOne hundred consecutive stage IV NSCLC patients (42 newly diagnosed, 58 with progression/recurrence) who underwent plasma cfDNA/ctDNA-based NGS analysis between January and November 2019 were retrospectively analyzed. Somatic mutations across 19 genes were assessed using the GeneRead QIAact Lung DNA UMI Panel (Qiagen) on the GeneReader platform.
resultsPathogenic mutations were detected in 25 patients (25%), yielding 34 PMs across seven genes. EGFR was most frequently mutated (52.9%), followed by KRAS (20.5%) and PIK3CA (14.5%). Multimetastatic patients had significantly higher cfDNA levels (10.0 ± 3.9 vs. 3.8 ± 1.0 ng; p = 0.01) and shorter OS (17.2 ± 5.5 vs. 49.5 ± 5.7 months; p < 0.001). Among EGFR wild-type patients with progression, resistance mutation carriers had markedly shorter OS (16.5 ± 0.5 vs. 48.7 ± 6.6 months; p = 0.001). KRAS G12C was the predominant KRAS variant (71%).
conclusionsNGS-based liquid biopsy identified actionable and resistance-associated mutations in 25% of advanced NSCLC patients in this Turkish Black Sea cohort. Total cfDNA concentration correlated with metastatic burden. The detection of KRAS G12C and EGFR T790M variants supports the complementary clinical utility of multi-gene plasma ctDNA panels alongside tissue genotyping in personalized treatment decisions, although confirmation in larger prospective cohorts with paired tissue analysis is warranted.
Indexed as
Identifiers
42176127What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.